Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
NASDAQ:NKTR
Price:
1.48 USD
12.12%
Updated:
Apr 29, 2024
Nektar Therapeutics
Revenue
|
Nektar Therapeutics
Revenue Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Revenue
$90.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-5%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45B
|
CAGR 3-Years
2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$60.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
Nektar Therapeutics
Revenue Breakdown
Breakdown by Geography
Nektar Therapeutics
Nektar Therapeutics
|
Total Revenue:
90.1m
USD
|
|
Non-Us:
78.6m
USD
|
|
United States:
11.5m
USD
|
Breakdown by Segments
Nektar Therapeutics
Nektar Therapeutics
|
Total Revenue:
90.1m
USD
|
|
Non Cash Royalty Revenue Related To Sale Of F...:
68.9m
USD
|
|
Product:
20.7m
USD
|
|
License Collaboration And Other Revenue:
520k
USD
|
See Also
What is Nektar Therapeutics's Revenue?
Revenue
90.1m
USD
90.1m
USD
Based on the financial report for Dec 31, 2023, Nektar Therapeutics's Revenue amounts to 90.1m USD.
What is Nektar Therapeutics's Revenue growth rate?
Revenue CAGR 10Y
-5%
-5%
Over the last year, the Revenue growth was -2%. The average annual Revenue growth rates for Nektar Therapeutics have been -16% over the past three years , -40% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet
